Brazil: New criteria for priority drug review

A public consultation on new criteria for prioritizing the review of drug approval applications is planned by Brazil's regulatory agency, ANVISA. 

The agency intends to propose a point system for determining which drugs should be "placed in front of the queue for review." 

According to the agency, an example of a marketing approval application that would get priority is for a generic version of a brand name drug that has no market competition. 